vs
Side-by-side financial comparison of Emerson Electric (EMR) and Stryker Corporation (SYK). Click either name above to swap in a different company.
Stryker Corporation is the larger business by last-quarter revenue ($7.2B vs $4.3B, roughly 1.7× Emerson Electric). Emerson Electric runs the higher net margin — 13.9% vs 11.8%, a 2.1% gap on every dollar of revenue. On growth, Stryker Corporation posted the faster year-over-year revenue change (11.4% vs 4.1%). Stryker Corporation produced more free cash flow last quarter ($1.9B vs $602.0M). Over the past eight quarters, Stryker Corporation's revenue compounded faster (16.9% CAGR vs -0.3%).
Emerson ElectricEMREarnings & Financial Report
Emerson Electric Co. is an American multinational corporation headquartered in St. Louis, Missouri. The Fortune 500 company delivers a range of engineering services, manufactures industrial automation equipment, climate control systems, and precision measurement instruments, and provides software engineering for industrial, commercial, and consumer markets.
The Stryker is a family of eight-wheeled armored fighting vehicles derived from the Canadian LAV III, which in turn derived from the Swiss Mowag Piranha. Stryker vehicles are produced by General Dynamics Land Systems-Canada (GDLS-C) for the United States Army in a plant in London, Ontario. It has four-wheel drive (8×4) and can be switched to all-wheel drive (8×8).
EMR vs SYK — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.3B | $7.2B |
| Net Profit | $605.0M | $849.0M |
| Gross Margin | 53.2% | 64.5% |
| Operating Margin | 17.8% | 25.2% |
| Net Margin | 13.9% | 11.8% |
| Revenue YoY | 4.1% | 11.4% |
| Net Profit YoY | 3.4% | 55.5% |
| EPS (diluted) | $1.07 | $2.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.3B | $7.2B | ||
| Q3 25 | $4.9B | $6.1B | ||
| Q2 25 | $4.6B | $6.0B | ||
| Q1 25 | $4.4B | $5.9B | ||
| Q4 24 | $4.2B | $6.4B | ||
| Q3 24 | $4.6B | $5.5B | ||
| Q2 24 | $4.4B | $5.4B | ||
| Q1 24 | $4.4B | $5.2B |
| Q4 25 | $605.0M | $849.0M | ||
| Q3 25 | $637.0M | $859.0M | ||
| Q2 25 | $586.0M | $884.0M | ||
| Q1 25 | $485.0M | $654.0M | ||
| Q4 24 | $585.0M | $546.0M | ||
| Q3 24 | $996.0M | $834.0M | ||
| Q2 24 | $329.0M | $825.0M | ||
| Q1 24 | $501.0M | $788.0M |
| Q4 25 | 53.2% | 64.5% | ||
| Q3 25 | 51.9% | 63.6% | ||
| Q2 25 | 52.6% | 63.8% | ||
| Q1 25 | 53.5% | 63.8% | ||
| Q4 24 | 53.5% | 64.9% | ||
| Q3 24 | 51.3% | 64.0% | ||
| Q2 24 | 52.8% | 63.0% | ||
| Q1 24 | 52.2% | 63.6% |
| Q4 25 | 17.8% | 25.2% | ||
| Q3 25 | 16.4% | 18.7% | ||
| Q2 25 | 16.1% | 18.5% | ||
| Q1 25 | 14.2% | 14.3% | ||
| Q4 24 | 18.6% | 9.0% | ||
| Q3 24 | 14.7% | 19.7% | ||
| Q2 24 | 10.4% | 19.4% | ||
| Q1 24 | 16.2% | 18.5% |
| Q4 25 | 13.9% | 11.8% | ||
| Q3 25 | 13.1% | 14.2% | ||
| Q2 25 | 12.9% | 14.7% | ||
| Q1 25 | 10.9% | 11.1% | ||
| Q4 24 | 14.0% | 8.5% | ||
| Q3 24 | 21.6% | 15.2% | ||
| Q2 24 | 7.5% | 15.2% | ||
| Q1 24 | 11.4% | 15.0% |
| Q4 25 | $1.07 | $2.20 | ||
| Q3 25 | $1.12 | $2.22 | ||
| Q2 25 | $1.04 | $2.29 | ||
| Q1 25 | $0.86 | $1.69 | ||
| Q4 24 | $1.02 | $1.41 | ||
| Q3 24 | $1.74 | $2.16 | ||
| Q2 24 | $0.57 | $2.14 | ||
| Q1 24 | $0.87 | $2.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $4.0B |
| Total DebtLower is stronger | $7.6B | — |
| Stockholders' EquityBook value | $20.3B | $22.4B |
| Total Assets | $41.9B | $47.8B |
| Debt / EquityLower = less leverage | 0.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.0B | ||
| Q3 25 | — | $3.3B | ||
| Q2 25 | — | $2.4B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $3.7B | ||
| Q3 24 | — | $3.9B | ||
| Q2 24 | — | $1.9B | ||
| Q1 24 | — | $2.3B |
| Q4 25 | $7.6B | — | ||
| Q3 25 | $8.9B | — | ||
| Q2 25 | $8.3B | — | ||
| Q1 25 | $8.2B | — | ||
| Q4 24 | $6.6B | — | ||
| Q3 24 | $7.7B | — | ||
| Q2 24 | $7.1B | — | ||
| Q1 24 | $7.6B | — |
| Q4 25 | $20.3B | $22.4B | ||
| Q3 25 | $20.3B | $21.8B | ||
| Q2 25 | $19.9B | $21.2B | ||
| Q1 25 | $19.2B | $20.9B | ||
| Q4 24 | $20.5B | $20.6B | ||
| Q3 24 | $21.6B | $20.1B | ||
| Q2 24 | $20.8B | $19.8B | ||
| Q1 24 | $20.9B | $19.2B |
| Q4 25 | $41.9B | $47.8B | ||
| Q3 25 | $42.0B | $47.1B | ||
| Q2 25 | $42.5B | $46.3B | ||
| Q1 25 | $42.0B | $46.0B | ||
| Q4 24 | $42.6B | $43.0B | ||
| Q3 24 | $44.2B | $43.8B | ||
| Q2 24 | $45.6B | $39.1B | ||
| Q1 24 | $46.4B | $39.4B |
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.44× | — | ||
| Q2 25 | 0.42× | — | ||
| Q1 25 | 0.42× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $699.0M | $2.1B |
| Free Cash FlowOCF − Capex | $602.0M | $1.9B |
| FCF MarginFCF / Revenue | 13.9% | 26.1% |
| Capex IntensityCapex / Revenue | 2.2% | 3.7% |
| Cash ConversionOCF / Net Profit | 1.16× | 2.52× |
| TTM Free Cash FlowTrailing 4 quarters | $4.4B | $4.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $699.0M | $2.1B | ||
| Q3 25 | $3.1B | $1.5B | ||
| Q2 25 | $1.1B | $1.1B | ||
| Q1 25 | $241.0M | $250.0M | ||
| Q4 24 | $777.0M | $1.9B | ||
| Q3 24 | $3.3B | $1.5B | ||
| Q2 24 | $1.1B | $633.0M | ||
| Q1 24 | $743.0M | $204.0M |
| Q4 25 | $602.0M | $1.9B | ||
| Q3 25 | $2.7B | $1.4B | ||
| Q2 25 | $977.0M | $928.0M | ||
| Q1 25 | $154.0M | $127.0M | ||
| Q4 24 | $694.0M | $1.7B | ||
| Q3 24 | $2.9B | $1.3B | ||
| Q2 24 | $998.0M | $481.0M | ||
| Q1 24 | $661.0M | $37.0M |
| Q4 25 | 13.9% | 26.1% | ||
| Q3 25 | 54.9% | 22.3% | ||
| Q2 25 | 21.5% | 15.4% | ||
| Q1 25 | 3.5% | 2.2% | ||
| Q4 24 | 16.6% | 25.9% | ||
| Q3 24 | 63.1% | 23.7% | ||
| Q2 24 | 22.8% | 8.9% | ||
| Q1 24 | 15.1% | 0.7% |
| Q4 25 | 2.2% | 3.7% | ||
| Q3 25 | 8.9% | 3.1% | ||
| Q2 25 | 2.0% | 3.0% | ||
| Q1 25 | 2.0% | 2.1% | ||
| Q4 24 | 2.0% | 4.1% | ||
| Q3 24 | 9.1% | 3.1% | ||
| Q2 24 | 2.1% | 2.8% | ||
| Q1 24 | 1.9% | 3.2% |
| Q4 25 | 1.16× | 2.52× | ||
| Q3 25 | 4.86× | 1.79× | ||
| Q2 25 | 1.83× | 1.26× | ||
| Q1 25 | 0.50× | 0.38× | ||
| Q4 24 | 1.33× | 3.54× | ||
| Q3 24 | 3.35× | 1.77× | ||
| Q2 24 | 3.31× | 0.77× | ||
| Q1 24 | 1.48× | 0.26× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EMR
| Other | $1.8B | 41% |
| Software And Systems | $1.0B | 24% |
| Intelligent Devices | $996.0M | 23% |
| Safety And Productivity | $503.0M | 12% |
SYK
| Medical | $1.3B | 18% |
| Endoscopy | $1.1B | 16% |
| Traumaand Extremities | $1.1B | 15% |
| Instruments | $925.0M | 13% |
| Knees | $749.0M | 10% |
| Neuro Cranial | $669.0M | 9% |
| Neurovascular | $539.0M | 8% |
| Hips | $499.0M | 7% |
| Other Orthopaedics | $267.0M | 4% |
| Spine | $8.0M | 0% |
